Geminiviral Vector System for Rituximab Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge in plant-based production of monoclonal antibodies like Rituximab is the low yield and instability of recombinant proteins, which is influenced by factors such as DNA element arrangement in viral replicons, plant developmental stage, and environmental conditions, making high-level production of functional proteins difficult.
Innovation Solution
An optimized geminiviral vector system is developed, comprising specific nucleic acid segments with promoters, UTRs, and terminators, along with Rep and RepA proteins, that allow independent and non-competing amplification and expression of Rituximab chains in Nicotiana benthamiana, enhancing protein production efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional plant transformation methods are used to produce monoclonal antibodies, then production can be sustained, but the yield remains low and protein stability is poor
Solution Approach 1:
The patent divides the monoclonal antibody production into separate replicons, with one replicon expressing the heavy chain and another expressing the light chain. This segmentation allows independent optimization of each chain's expression and stability, resolving the contradiction between achieving high yield and maintaining protein stability through coordinated expression from multiple specialized replicons
Solution Approach 2:
The patent creates a composite viral system by combining multiple geminiviral replicons (ACYMV and BEYDV) with complementary functions. The ACYMV replicon provides stable maintenance while the BEYDV replicon provides high-level expression, creating a composite system that achieves both high productivity and reliability simultaneously
2Productivity
If viral replicons are used to enhance protein expression, then production level increases, but expression becomes affected by DNA element arrangement, plant developmental stage, and environmental factors
Solution Approach 1:
The patent segments the viral replicon system into functionally specialized components: ACYMV replicon optimized for stable DNA maintenance and BEYDV replicon optimized for high-level transcription and translation. This segmentation reduces the impact of environmental variables on overall system performance by distributing functions across specialized modules
Solution Approach 2:
The patent optimizes specific parameters within each replicon including promoter strength (35S promoter), transcriptional control elements, and replicon structure to achieve high expression levels while maintaining stability. These parameter optimizations make the system more robust to environmental variations
3Device complexity
If multiple nucleic acid segments are combined in a single vector, then expression complexity increases, but system stability and independent amplification may be compromised
Solution Approach 1:
The patent physically separates multiple nucleic acid segments into different viral replicons (ACYMV and BEYDV), each capable of independent replication and maintenance. This segmentation ensures that each replicon can amplify independently without interfering with others, maintaining reliability while achieving complex multi-gene expression
Solution Approach 2:
The patent nests multiple functional elements within a hierarchical vector structure where outer viral replicons contain inner expression cassettes. The ACYMV and BEYDV replicons are nested within Agrobacterium T-DNA boundaries, creating a nested architecture that maintains both complexity and stability
Data Source
AI summary
A single vector or multiple separate vectors that contain two or more non-competing replicons for transient expression of the heavy and light chains of Rituximab in Nicotiana benthamiana leaves is described. The correct assembly of these subunit proteins into functional oligomeric structures to optimize the expression is also described. This system advances plant transient expression technology by eliminating the need for non-competing viruses, and thus, enhances the realistic commercial application of the multi-replicon single vector system for producing Rituximab in plant cells.